Pathological and Molecular Alterations after First and Second Generation EGFR-TKI Therapy in Patients with EGFR-Mutated Lung Adenocarcinomas

被引：0
|
作者：
Uruga, H. [1 ]
Fujii, T. [2 ]
Yamamoto, G. [1 ]
Moriguchi, S. [1 ]
Takahashi, Y. [1 ]
Ogawa, K. [1 ]
Murase, R. [1 ]
Mochizuki, S. [1 ]
Hanada, S. [1 ]
Takaya, H. [1 ]
Miyamoto, A. [1 ]
Morokawa, N. [1 ]
Kishi, K. [1 ]
机构：
[1] Toranomon Gen Hosp, Dept Resp Med, Resp Ctr, Tokyo, Japan
[2] Toranomon Gen Hosp, Dept Pathol, Tokyo, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
EGFR-TKI; lung adenocarcinoma; Pathological alteration;
D O I：
10.1016/j.jtho.2017.09.1563
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.02-033
引用
收藏
页码：S2249 / S2249
页数：1
相关论文
共 50 条
  • [1] Clinical Impact of Switching to a Second EGFR-TKI After a Severe AE Related to a First EGFR-TKI in EGFR-mutated NSCLC
    Takeda, Masayuki
    Okamoto, Isamu
    Tsurutani, Junji
    Oiso, Naoki
    Kawada, Akira
    Nakagawa, Kazuhiko
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 42 (06) : 528 - 533
  • [2] Overcoming EGFR-TKI resistance in EGFR-mutated lung cancer
    Gardizi, M.
    Scheffler, M.
    Bos, M.
    Geist, T.
    Heukamp, L.
    Nogova, L.
    Toepelt, K.
    Fernandez-Cuesta, L.
    Culmann, H.
    Kaminsky, B.
    Panse, J.
    Becker, C.
    Mattonet, C.
    Serke, M.
    Schmitz, S.
    Schnell, R.
    Galetke, W.
    Hekmat, K.
    Buettner, R.
    Wolf, J.
    ONKOLOGIE, 2013, 36 : 30 - 30
  • [3] EGFR-TKI plus /- Antiangiogenics for EGFR-mutated Advanced NSCLC
    da Silva, L. L.
    Matsas, S.
    Aguiar, P., Jr.
    Taveira, G. M. T.
    Barcelos, I. F.
    Lopes, G. L., Jr.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S416 - S417
  • [4] EGFR-TKI plus brain radiotherapy versus EGFR-TKI alone in the management of EGFR-mutated NSCLC patients with brain metastases
    Dong, Kai
    Liang, Wenhua
    Zhao, Shen
    Guo, Minzhang
    He, Qihua
    Li, Caichen
    Song, Haiqing
    He, Jianxing
    Xia, Xiaojun
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 (03) : 268 - +
  • [5] Clinical advances in EGFR-TKI combination therapy for EGFR-mutated NSCLC: a narrative review
    Zhang, Qianru
    Wang, Ruo
    Xu, Lu
    TRANSLATIONAL CANCER RESEARCH, 2023, 12 (12) : 3764 - 3778
  • [6] Pooled safety analysis of EGFR-TKI therapy in patients with EGFR-mutated non-small cell lung cancer.
    Takada, Masayuki
    Okamoto, Isamu
    Nakagawa, Kazuhiko
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [7] CHRONIC NICOTINE EXPOSURE MEDIATES RESISTANCE TO EGFR-TKI IN EGFR-MUTATED LUNG CANCER VIA EGFR SIGNAL
    Hayashi, Hidetoshi
    Togashi, Yosuke
    Okamoto, Kunio
    Fumita, Soichi
    Terashima, Masato
    Sakai, Kazuko
    Fujita, Yoshihiko
    Tomida, Shuta
    Nakagawa, Kazuhiko
    Nishio, Kazuto
    ANNALS OF ONCOLOGY, 2014, 25
  • [8] Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR-mutated lung cancer via an EGFR signal
    Togashi, Yosuke
    Hayashi, Hidetoshi
    Okamoto, Kunio
    Fumita, Soichi
    Terashima, Masato
    de Velasco, Marco A.
    Sakai, Kazuko
    Fujita, Yoshihiko
    Tomida, Shuta
    Nakagawa, Kazuhiko
    Nishio, Kazuto
    LUNG CANCER, 2015, 88 (01) : 16 - 23
  • [9] Feasibility and safety of EGFR-TKI neoadjuvant therapy for EGFR-mutated NSCLC: A meta-analysis
    Zhuchen Yu
    Fei Xu
    Juntao Zou
    European Journal of Clinical Pharmacology, 2024, 80 : 505 - 517
  • [10] Feasibility and safety of EGFR-TKI neoadjuvant therapy for EGFR-mutated NSCLC: A meta-analysis
    Yu, Zhuchen
    Xu, Fei
    Zou, Juntao
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 80 (04) : 505 - 517
12345